Cidara Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Cidara Therapeutics kazanç ve gelirinin sırasıyla yıllık 8.4% ve 72% oranında artması tahmin edilirken, EPS'nin yıllık 37.2% oranında büyümesi bekleniyor.

Anahtar bilgiler

8.4%

Kazanç büyüme oranı

37.2%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.2%
Gelir büyüme oranı	72.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	18 Mar 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention

Feb 11

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

Sep 28

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Apr 17

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Mar 25

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Aug 09

Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts

Dec 17

Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic

Aug 17

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:CDTX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	6	-179	-94	-74	5
12/31/2026	N/A	-159	-91	-130	6
12/31/2025	N/A	-136	-107	-142	6
12/31/2024	1	-170	-177	-177	N/A
9/30/2024	45	-124	-160	-160	N/A
6/30/2024	54	-112	-125	-125	N/A
3/31/2024	59	-24	-19	-18	N/A
12/31/2023	23	-25	-23	-22	N/A
9/30/2023	31	-34	-31	-31	N/A
6/30/2023	62	-18	-1	-1	N/A
3/31/2023	64	-22	-16	-16	N/A
12/31/2022	23	-22	-29	-28	N/A
9/30/2022	61	-33	-22	-22	N/A
6/30/2022	28	-63	-62	-62	N/A
3/31/2022	54	-44	-47	-47	N/A
12/31/2021	50	-42	-25	-25	N/A
9/30/2021	46	-47	-21	-21	N/A
6/30/2021	41	-47	-24	-24	N/A
3/31/2021	12	-74	-41	-41	N/A
12/31/2020	12	-75	-55	-54	N/A
9/30/2020	10	-67	-59	-58	N/A
6/30/2020	27	-47	-28	-28	N/A
3/31/2020	23	-42	-27	-27	N/A
12/31/2019	21	-41	-29	-29	N/A
9/30/2019	19	-39	-27	-27	N/A
6/30/2019	N/A	-56	-57	-56	N/A
3/31/2019	N/A	-69	-59	-59	N/A
12/31/2018	N/A	-69	-57	-57	N/A
9/30/2018	N/A	-70	N/A	-53	N/A
6/30/2018	N/A	-69	N/A	-54	N/A
3/31/2018	N/A	-59	N/A	-50	N/A
12/31/2017	N/A	-56	N/A	-50	N/A
9/30/2017	N/A	-57	N/A	-52	N/A
6/30/2017	N/A	-57	N/A	-46	N/A
3/31/2017	N/A	-52	N/A	-43	N/A
12/31/2016	N/A	-48	N/A	-40	N/A
9/30/2016	N/A	-44	N/A	-35	N/A
6/30/2016	N/A	-41	N/A	-34	N/A
3/31/2016	N/A	-35	N/A	-31	N/A
12/31/2015	N/A	-32	N/A	-26	N/A
9/30/2015	N/A	-27	N/A	-22	N/A
6/30/2015	N/A	-21	N/A	-18	N/A
3/31/2015	N/A	-18	N/A	-13	N/A
12/31/2014	N/A	-12	N/A	-8	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: CDTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: CDTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: CDTX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: CDTX gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: CDTX gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: CDTX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/03/24 08:39
Gün Sonu Hisse Fiyatı	2025/03/21 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Cidara Therapeutics, Inc. 15 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Timothy Chiang	BTIG
Chiara Russo	Cantor Fitzgerald & Co.
Eric Schmidt	Cantor Fitzgerald & Co.

Cidara Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus estimates of losses per share improve by 21%

Forecast to breakeven in 2025

Consensus revenue estimates fall by 30%

Forecast to breakeven in 2025

Consensus revenue estimates increase by 85%

Forecast to breakeven in 2023

Recent updates

Cidara Therapeutics, Inc. Announces Two Presentations on Cd388 in Influenza At International Conference on Antiviral Research 2025

Cidara Therapeutics Announces Publication of Cd388 Preclinical Data in Nature Microbiology

Cidara Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective February 24, 2025

Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention

Cidara Therapeutics, Inc. Announces Management Changes

Cidara Therapeutics, Inc. Completes Enrollment of Phase 2b NAVIGATE Trial Evaluating CD388 for Prevention of Seasonal Influenza

Cidara Therapeutics, Inc. announced that it expects to receive $104.999685 million in funding from a group of investors

Cidara Therapeutics, Inc. Announces the Appointment of Scientific Advisory Board Members

Cidara Therapeutics, Inc. Announces Reduction in Workforce to Focus on Planned Clinical Development of CD388

Cidara Therapeutics Appoints Jim Beitel as Chief Business Officer

Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Value Index

Cidara Therapeutics, Inc., Annual General Meeting, Jul 18, 2024

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

Napp Pharmaceutical Group Ltd. acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc. (NasdaqCM:CDTX).

Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors

Cidara Therapeutics, Inc. announced delayed annual 10-K filing

Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id

Cidara Therapeutics Requests a Hearing Before the Nasdaq Hearings Panel

Consensus estimates of losses per share improve by 21%

New minor risk - Profitability

Forecast to breakeven in 2025

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth

New major risk - Financial position

Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development

Consensus revenue estimates fall by 30%

New minor risk - Profitability

Forecast to breakeven in 2025

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cidara Therapeutics Provides Update on REZZAYO™ (Rezafungin for Injection)

Cidara Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

New minor risk - Market cap size

Cidara Therapeutics, Inc. to Present Highlights from Its Ongoing Preclinical Studies of CD421 as Well as the Development of Its Novel Drug-Fc Conjugates from Cidara’s Cloudbreak® Platform

Consensus revenue estimates increase by 85%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year

Full year 2022 earnings: EPS misses analyst expectations

Forecast to breakeven in 2023

We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Price target decreased to US$5.50

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from Its Cloudbreak Platform

Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

High number of new directors

Consensus revenue estimates increase by 67%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cidara Therapeutics Attends Hearing Before the Nasdaq Hearings Panel and Presents Plan to Regain Compliance with the Nasdaq Capital Market

Cidara spikes on $11M milestone payment from partner Mundipharma

Cidara Therapeutics, Inc. Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics Announces Initiation of Phase 2A Human Viral Challenge Trial to Evaluate Cd388 for Universal Prevention of Influenza

Cidara begins dosing of antiviral CD388 in trial for preventing influenza

Cidara Therapeutics, Inc. Announces Executive Changes

Consensus revenue estimates increase by 53%

Second quarter 2022 earnings: EPS exceeds analyst expectations

Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M

Cidara Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$5.67

High number of new directors

Mundipharma and Cidara Therapeutics Announces First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile

Cidara Therapeutics, Inc. Announces Executive Changes

Cidara Therapeutics, Inc. Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza